OHSU

David Qian, Ph.D.

Head Shot of David Qian
Email: 
click here

Background

Dr. Qian’s laboratory studies the molecular and cellular mechanism of chemotherapy stress response and resistance and the epigenetics of hypoxia. The lab is investigating ways to target prostate cancer cells and angiogenesis with HDAC inhibitors.


Selected Publications

"Genetic profiling to determine risk of relapse-free survival in high-risk localized prostate cancer," Clinical Cancer Research (Vol: 20, Issue: 5, Page 1306-1312) - 2014

"Malate dehydrogenase 2 confers docetaxel resistance via regulations of JNK signaling and oxidative metabolism," Prostate (Vol: 73, Issue: 10, Page 1028-1037) - 2013

"HIF1α protein stability is increased by acetylation at lysine 709," Journal of Biological Chemistry (Vol: 287, Issue: 42, Page 35496-35505) - 2012

"Phase i study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours," British Journal of Cancer (Vol: 106, Issue: 1, Page 77-84) - 2012

"A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma," Science Translational Medicine (Vol: 3, Issue: 85, ) - 2011

 

Contact

  Email David Qian

503 312-5912

Memberships & Associations

American Association for Cancer Research